rosiglitazone has been researched along with Vascular Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, HW; Hu, CP; Li, YJ; Peng, SM; Tan, LF; Zou, XQ | 1 |
| Dou, XZ; Duerfeldt, AS; Ma, JX; Nath, D; Shin, Y | 1 |
| Krentz, A | 1 |
| Abdul Rahman, AR; Ismail, AA; Ismail, SB; Naing, NN; Rahman, S | 1 |
1 review(s) available for rosiglitazone and Vascular Diseases
| Article | Year |
|---|---|
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Vascular Diseases | 2009 |
1 trial(s) available for rosiglitazone and Vascular Diseases
| Article | Year |
|---|---|
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arteries; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Middle Aged; Pulsatile Flow; Ramipril; Rosiglitazone; Stroke Volume; Thiazolidinediones; Vascular Diseases | 2007 |
2 other study(ies) available for rosiglitazone and Vascular Diseases
| Article | Year |
|---|---|
Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.
Topics: Aldehyde Reductase; Cysteine; Flavonoids; Glycation End Products, Advanced; Hep G2 Cells; Humans; Nitric Oxide; Oxadiazoles; Vascular Diseases | 2011 |
Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARĪ± selective agonists: New leads for oculovascular conditions.
Topics: Dose-Response Relationship, Drug; Eye Diseases; Humans; Ligands; Models, Molecular; Molecular Structure; PPAR alpha; Quinolines; Structure-Activity Relationship; Vascular Diseases | 2018 |